Close this window

Board Change: Non-Executive Director Appointment

11/18/2026
RNS Number : 5566D
Genus PLC
18 November 2026
 

18 November 2026

Genus plc

(“Genus” or the “Group”)

Board Change: Non-Executive Director Appointment

 

Genus (LSE: GNS), a leading global animal genetics company, is pleased to announce the appointment of Sharmila Nebhrajani to the Board as a Non-Executive Director, with effect from 1 January 2027.  

Ms Nebhrajani is a Chartered Accountant with extensive experience in public sector, commercial, government and non-profit organisations across a wide range of sectors, having worked in senior roles in public health and medical research, working with government, medical charities and pharmaceutical industry partners, and latterly in government, convening international policy dialogue with governments, multi-lateral agencies, NGOs, senior policy makers and academics, on key global policy issues. Her appointment follows an extensive search process using an external search agency.

Ms Nebhrajani has a MA in Physiological Sciences from Oxford University and is currently a non-executive director and remuneration committee chair of Severn Trent plc[1], non-executive director and remuneration committee chair of ITV plc, senior independent director and audit committee chair of Halma plc, non-executive director of Essentra plc and Chair of the National Institute for Health and Care Excellence. She was previously a non-executive director of Coutts & Co.  

Commenting on the appointment, Iain Ferguson, Chair of Genus, said:

“We are delighted to welcome Shar to the Board. Shar is a highly experienced non-executive director and audit committee chair, and brings a broad range of commercial, strategic and scientific experience and knowledge.” 

For further information please contact:

Genus plc Tel: +44 (0)1256 345 970

Iain Ferguson, Chair

Jorgen Kokke, Chief Executive Officer

Tavistock            Tel: +44 (0)20 7920 3150 

 

Nick Dibden / Katie Hopkins 

 

 About Genus

Genus is a world-leading animal genetics company. Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

Genus's worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chains.

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.

With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

Regulatory Notes

Details of any payments to be made to Sharmila Nebhrajani will be disclosed in full in the Company’s 2027 Directors’ Remuneration Report.  Any such terms will be consistent with the Company's approved Directors’ Remuneration Policy.

 

This announcement is made in accordance with Listing Rule 6.4.6R.   There are no matters to be disclosed in connection with Listing Rule 6.4.8R (2) – (6). The person responsible for making this announcement on behalf of the Group is Lucie Grant (General Counsel and Company Secretary).

 


[1] Sharmila will step down from the Board of Severn Trent plc on 30 November 2026.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAMZMMMKNVGVZM

Multimedia Files:

Close this window